Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.

Paolo Ghia,Andrzej Pluta,Malgorzata Wach,Daniel Lysák,Tomas Kozak,Martin Simkovic,Polina Kaplan,Iryna Kraychok,Árpád Illés,Javier de la Serna,Sean Dolan,Philip Campbell,Gerardo Musuraca,Abraham Jacob,Eric Joseph Avery,Jae Hoon Lee,Denise Wang,Priti Patel,Cheng Seok Quah,Wojciech Jurczak

Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.

2020

8015Background: Acala is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients (pts) with CLL including those with R/R CLL. The efficacy and safety of...

Keywords:

Bendamustine
Idelalisib
Internal medicine
Oncology
Acalabrutinib
Medicine
Pathology
Chronic lymphocytic leukemia
relapsed refractory
Rituximab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations